Log in

Relevant bibliographies by topics / Pharmacokinetic interactions / Journal articles

To see the other types of publications on this topic, follow the link: Pharmacokinetic interactions.

Journal articles on the topic 'Pharmacokinetic interactions'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pharmacokinetic interactions.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Keirns, J., T. Sawamoto, M. Holum, D. Buell, W. Wisemandle, and A. Alak. "Steady-State Pharmacokinetics of Micafungin and Voriconazole after Separate and Concomitant Dosing in Healthy Adults." Antimicrobial Agents and Chemotherapy 51, no. 2 (2006): 787–90. http://dx.doi.org/10.1128/aac.00673-06.

Full text

Abstract:

ABSTRACT We assessed the pharmacokinetics and interactions of steady-state micafungin (Mycamine) or placebo with steady-state voriconazole in 35 volunteers. The 90% confidence intervals around the least-squares mean ratios for micafungin pharmacokinetic parameters and placebo-corrected voriconazole pharmacokinetic parameters were within the 80%-to-125% limits, indicating an absence of drug interaction.

APA, Harvard, Vancouver, ISO, and other styles

2

Taylor, David. "Pharmacokinetic interactions involving clozapine." British Journal of Psychiatry 171, no. 2 (1997): 109–12. http://dx.doi.org/10.1192/bjp.171.2.109.

Full text

Abstract:

BackgroundMetabolism of clozapine is complex and not fully understood. Pharmacokinetic interactions with other drugs have been described but, in some cases, their mechanism is unknown.MethodPublished trials and case reports relevant to the human metabolism of clozapine and to suspected pharmacokinetic interactions were reviewed.ResultsMetabolism of clozapine appears to be largely controlled by the function of the hepatic cytochrome p4501A2 (CYPIA2). Compounds which induce CYPIA2 activity (carbamazepine, tobacco smoke) may reduce plasma clozapine levels. Inhibitors of CYPIA2 (caffeine, erythrom

APA, Harvard, Vancouver, ISO, and other styles

3

Soyata, Amelia, Aliya Nur Hasanah, and Taofik Rusdiana. "Interaction of Warfarin with Herbs Based on Pharmacokinetic and Pharmacodynamic Parameters." Indonesian Journal of Pharmaceutics 2, no. 2 (2020): 69. http://dx.doi.org/10.24198/idjp.v2i2.27289.

Full text

Abstract:

Warfarin is an oral anticoagulant that has been widely used and has strong efficacy, but the use of warfarin is still a concern because of its narrow therapeutic index which cause interactions when co-administration with drugs, herbs or food. This interaction can affect the pharmacokinetics and pharmacodynamics of warfarin and the most fatal effect from warfarin interactions is bleeding. In this review article data on warfarin-herbs interactions were collected based on pharmacokinetic parameters (AUC0-∞, Cmax, T1/2, Cl/F, and V/F), while pharmacodynamic parameters (International normalized rat

APA, Harvard, Vancouver, ISO, and other styles

4

Costache, Irina-Iuliana, Anca Miron, Monica Hăncianu, Viviana Aursulesei, Alexandru Dan Costache, and Ana Clara Aprotosoaie. "Pharmacokinetic Interactions between Cardiovascular Medicines and Plant Products." Cardiovascular Therapeutics 2019 (September 2, 2019): 1–19. http://dx.doi.org/10.1155/2019/9402781.

Full text

Abstract:

The growing use of plant products among patients with cardiovascular pharmacotherapy raises the concerns about their potential interactions with conventional cardiovascular medicines. Plant products can influence pharmacokinetics or/and pharmacological activity of coadministered drugs and some of these interactions may lead to unexpected clinical outcomes. Numerous studies and case reports showed various pharmacokinetic interactions that are characterized by a high degree of unpredictability. This review highlights the pharmacokinetic clinically relevant interactions between major conventional

APA, Harvard, Vancouver, ISO, and other styles

5

Cohen, Lawrence J., and C. Lindsay DeVane. "Clinical Implications of Antidepressant Pharmacokinetics and Pharmacogenetics." Annals of Pharmacotherapy 30, no. 12 (1996): 1471–80. http://dx.doi.org/10.1177/106002809603001216.

Full text

Abstract:

OBJECTIVE: To review available data on pharmacokinetic and pharmacogenetic influences on the response to antidepressant therapy, analyze the mechanisms for and clinical significance of pharmacokinetic and pharmacogenetic differences, and explain the implications of pharmacokinetics and pharmacogenetics for patient care. DATA SOURCES: A MEDLINE search of English-language clinical studies, abstracts, and review articles on antidepressant pharmacokinetics, pharmacogenetics, and drug interactions was used to identify pertinent literature. DATA SYNTHESIS: The pharmacokinetic profiles of selected an

APA, Harvard, Vancouver, ISO, and other styles

6

ERESHEFSKY, LARRY, STEPHEN R. SAKLAD, MARK D. WATANABE, CHESTER M. DAVIS, and MICHAEL W. JANN. "Thiothixene Pharmacokinetic Interactions." Journal of Clinical Psychopharmacology 11, no. 5 (1991): 296???301. http://dx.doi.org/10.1097/00004714-199110000-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Hartshorn, Edward A. "Pharmacokinetic Drug Interactions." Journal of Pharmacy Technology 1, no. 5 (1985): 193–99. http://dx.doi.org/10.1177/875512258500100505.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Eichelbaum, Michel. "Pharmacokinetic Drug Interactions." Journal of Clinical Pharmacology 26, no. 6 (1986): 469–73. http://dx.doi.org/10.1002/j.1552-4604.1986.tb03560.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Pukrittayakamee, Sasithon, Joel Tarning, Podjanee Jittamala, et al. "Pharmacokinetic Interactions between Primaquine and Chloroquine." Antimicrobial Agents and Chemotherapy 58, no. 6 (2014): 3354–59. http://dx.doi.org/10.1128/aac.02794-13.

Full text

Abstract:

ABSTRACTChloroquine combined with primaquine has been the standard radical curative regimen forPlasmodium vivaxandPlasmodium ovalemalaria for over half a century. In an open-label crossover pharmacokinetic study, 16 healthy volunteers (4 males and 12 females) aged 20 to 47 years were randomized into two groups of three sequential hospital admissions to receive a single oral dose of 30 mg (base) primaquine, 600 mg (base) chloroquine, and the two drugs together. The coadministration of the two drugs did not affect chloroquine or desethylchloroquine pharmacokinetics but increased plasma primaquin

APA, Harvard, Vancouver, ISO, and other styles

10

Marvanova, Marketa. "Pharmacokinetic characteristics of antiepileptic drugs (AEDs)." Mental Health Clinician 6, no. 1 (2016): 8–20. http://dx.doi.org/10.9740/mhc.2015.01.008.

Full text

Abstract:

Abstract Antiepileptic drugs (AEDs) are routinely prescribed for the management of a variety of neurologic and psychiatric conditions, including epilepsy and epilepsy syndromes. Physiologic changes due to aging, pregnancy, nutritional status, drug interactions, and diseases (ie, those involving liver and kidney function) can affect pharmacokinetics of AEDs. This review discusses foundational pharmacokinetic characteristics of AEDs currently available in the United States, including clobazam but excluding the other benzodiazepines. Commonalities of pharmacokinetic properties of AEDs are discuss

APA, Harvard, Vancouver, ISO, and other styles

11

Kalam, Muhammad Nasir, Muhammad Fawad Rasool, Asim Ur Rehman, and Naveed Ahmed. "Clinical Pharmacokinetics of Propranolol Hydrochloride: A Review." Current Drug Metabolism 21, no. 2 (2020): 89–105. http://dx.doi.org/10.2174/1389200221666200414094644.

Full text

Abstract:

Background: Nobel laureate Sir James Black’s molecule, propranolol, still has broad potential in cardiovascular diseases, infantile haemangiomas and anxiety. A comprehensive and systematic review of the literature for the summarization of pharmacokinetic parameters would be effective to explore the new safe uses of propranolol in different scenarios, without exposing humans and using virtual-human modeling approaches. Objective: This review encompasses physicochemical properties, pharmacokinetics and drug-drug interaction data of propranolol collected from various studies. Methods: Clinical ph

APA, Harvard, Vancouver, ISO, and other styles

12

Sumartin, Yunita, and Elin Yulinah Sukandar. "STUDI INTERAKSI OBAT-OBAT JANTUNG YANG DILAKUKAN TERHADAP ORANG SEHAT: TINJAUAN SISTEMATIS." Kartika : Jurnal Ilmiah Farmasi 9, no. 2 (2024): 128–46. http://dx.doi.org/10.26874/kjif.v9i2.669.

Full text

Abstract:

Pasien dengan penyakit kardiovaskular memiliki prevalensi interaksi obat yang lebih tinggi dibandingkan kelompok pasien lain karena jumlah dan penggunaan obat yang komplek. Interaksi obat merupakan perubahan efek kerja dari suatu obat karena adanya obat lain ketika diberikan bersamaan. Jenis interaksi obat terdiri dari interaksi farmakokinetik, farmakodinamik, dan farmasetik. Studi ini berupa tinjauan sistematis yang bertujuan untuk mengidentifikasi interaksi obat yang berkaitan dengan obat-obat jantung. Proses penelusuran artikel dilakukan pada database PubMed dan ScienceDirect untuk mengiden

APA, Harvard, Vancouver, ISO, and other styles

13

Rodin, Steven M., and Brian F. Johnson. "Pharmacokinetic Interactions with Digoxin." Clinical Pharmacokinetics 15, no. 4 (1988): 227–44. http://dx.doi.org/10.2165/00003088-198815040-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Glue, Paul, Christopher R. Banfield, James L. Perhach, Gary G. Mather, Jagdish K. Racha, and Rene H. Levy. "Pharmacokinetic Interactions with Felbamate." Clinical Pharmacokinetics 33, no. 3 (1997): 214–24. http://dx.doi.org/10.2165/00003088-199733030-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Niemi, Mikko, Janne T. Backman, Martin F. Fromm, Pertti J. Neuvonen, and Kari T. Kivist?? "Pharmacokinetic Interactions with Rifampicin." Clinical Pharmacokinetics 42, no. 9 (2003): 819–50. http://dx.doi.org/10.2165/00003088-200342090-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Bialer, Meir, Dennis R. Doose, Bindu Murthy, et al. "Pharmacokinetic Interactions of Topiramate." Clinical Pharmacokinetics 43, no. 12 (2004): 763–80. http://dx.doi.org/10.2165/00003088-200443120-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Scheen, Andr?? J. "Pharmacokinetic Interactions with Thiazolidinediones." Clinical Pharmacokinetics 46, no. 1 (2007): 1–12. http://dx.doi.org/10.2165/00003088-200746010-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Olanzapine + fluvoxamine: pharmacokinetic interactions." Inpharma Weekly &NA;, no. 1362 (2002): 20. http://dx.doi.org/10.2165/00128413-200213620-00050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Reinoso, R. F., A. Sánchez Navarro, M. J. García, and J. R. Prous. "Pharmacokinetic interactions of statins." Methods and Findings in Experimental and Clinical Pharmacology 23, no. 10 (2001): 541. http://dx.doi.org/10.1358/mf.2001.23.10.677120.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Baciewicz, Anne M., and Frank A. Baciewicz. "Cyclosporine pharmacokinetic drug interactions." American Journal of Surgery 157, no. 2 (1989): 264–71. http://dx.doi.org/10.1016/0002-9610(89)90541-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Goswami, Suchandra, Shivangi Saxena, Shalini Yadav, et al. "Review of Curcumin and Its Different Formulations: Pharmacokinetics, Pharmacodynamics and Pharmacokinetic-Pharmacodynamic Interactions." OBM Integrative and Complementary Medicine 07, no. 04 (2022): 1–35. http://dx.doi.org/10.21926/obm.icm.2204057.

Full text

Abstract:

Curcumin, the yellow principle of the Indian Turmeric, ‘Haldi’ has recently attracted renewed interest in the field of experimental medicine with pleiotropic activity. This review has emphasized three pharmaceutical studies of interest: the pharmacokinetics, pharmacology, and pharmacodynamics of curcumin. In this review, we attempted to review the general pharmacokinetics profile, pharmacokinetic interactions, and pharmacokinetic-pharmacodynamic interactions of curcumin and its formulations. Different species of turmeric in India, as well as their cultivars, different forms of curcumin, and ha

APA, Harvard, Vancouver, ISO, and other styles

22

Sun, Lei, Kun Mi, Yixuan Hou, et al. "Pharmacokinetic and Pharmacodynamic Drug–Drug Interactions: Research Methods and Applications." Metabolites 13, no. 8 (2023): 897. http://dx.doi.org/10.3390/metabo13080897.

Full text

Abstract:

Because of the high research and development cost of new drugs, the long development process of new drugs, and the high failure rate at later stages, combining past drugs has gradually become a more economical and attractive alternative. However, the ensuing problem of drug–drug interactions (DDIs) urgently need to be solved, and combination has attracted a lot of attention from pharmaceutical researchers. At present, DDI is often evaluated and investigated from two perspectives: pharmacodynamics and pharmacokinetics. However, in some special cases, DDI cannot be accurately evaluated from a si

APA, Harvard, Vancouver, ISO, and other styles

23

Liang, Liuyi, Xin Jin, Jinjing Li, et al. "A Comprehensive Review of Pharmacokinetics and Pharmacodynamics in Animals: Exploration of Interaction with Antibiotics of Shuang-Huang- Lian Preparations." Current Topics in Medicinal Chemistry 22, no. 2 (2022): 83–94. http://dx.doi.org/10.2174/1568026621666211012111442.

Full text

Abstract:

: As a traditional Chinese medicine (TCM), Shuang-Huang-Lian (SHL) has been widely used for treating infectious diseases of the respiratory tract such as encephalitis, pneumonia, and asthma. During the past few decades, considerable research has focused on pharmacological action, pharmacokinetic interaction with antibiotics, and clinical applications of SHL. A huge and more recent body of pharmacokinetic studies support the combination of SHL and antibiotics have different effects such as antagonism and synergism. SHL has been one of the best-selling TCM products. However, there is no systemat

APA, Harvard, Vancouver, ISO, and other styles

24

Ahmane, Amel, Hocine Gacem, Karim Boulesbiaat, and Meriem Boullelli. "Pharmacokinetic interactions: from mechanisms to clinical relevance." Batna Journal of Medical Sciences (BJMS) 1, no. 2 (2014): 85–95. http://dx.doi.org/10.48087/bjmstf.2014.1209.

Full text

Abstract:

Among the various types of known drug interactions, those involving pharmacokinetic processes are more complex and dangerous. From digestive pH changes to plasma protein binding and induction or inhibition phenomena; current data used to define, with precision, the sites of interaction. The enzymes involved in metabolism, the transporters involved in tissue distribution and excretion of drugs, and nuclear receptors that regulate the expression of these enzymes and transporters are keys determinants that should be defined for each drug. The clinical relevance of a pharmacokinetic interaction is

APA, Harvard, Vancouver, ISO, and other styles

25

Zerjav, Sylvia, Gordon Tse, and Michael J. W. Scott. "Review of Duloxetine and Venlafaxine in Depression." Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 142, no. 3 (2009): 144–52. http://dx.doi.org/10.3821/1913-701x-142.3.144.

Full text

Abstract:

Objectives: To compare the efficacy and pharmacologic, pharmacokinetic, drug interaction and adverse effect profiles of duloxetine and venlafaxine. Methods: A systematic review of the literature pertaining to duloxetine and venlafaxine was conducted using a computer-aided search of MEDLINE and EMBASE for the period January 1988 to May 2008 with the following search terms: venlafaxine and duloxetine and depression, clinical studies, pharmacology, drug interactions, pharmacokinetics, adverse effects, safety, case reports and review articles. Results: Duloxetine and venlafaxine have comparable ef

APA, Harvard, Vancouver, ISO, and other styles

26

Dukaew, Nahathai, Patcharawadee Thongkumkoon, Nutnicha Sirikaew, et al. "Gut Microbiota-Mediated Pharmacokinetic Drug–Drug Interactions between Mycophenolic Acid and Trimethoprim-Sulfamethoxazole in Humans." Pharmaceutics 15, no. 6 (2023): 1734. http://dx.doi.org/10.3390/pharmaceutics15061734.

Full text

Abstract:

Mycophenolic acid (MPA) and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly prescribed together in certain groups of patients, including solid organ transplant recipients. However, little is known about the pharmacokinetic drug–drug interactions (DDIs) between these two medications. Therefore, the present study aimed to determine the effects of TMP-SMX on MPA pharmacokinetics in humans and to find out the relationship between MPA pharmacokinetics and gut microbiota alteration. This study enrolled 16 healthy volunteers to take a single oral dose of 1000 mg mycophenolate mofetil (MMF), a pr

APA, Harvard, Vancouver, ISO, and other styles

27

Hofmeister, Craig C., Xiaoxia Yang, Flavia Pichiorri, et al. "Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein." Journal of Clinical Oncology 29, no. 25 (2011): 3427–34. http://dx.doi.org/10.1200/jco.2010.32.4962.

Full text

Abstract:

Purpose Multiple myeloma (MM) is an incurable plasma-cell neoplasm for which most treatments involve a therapeutic agent combined with dexamethasone. The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM. Patients and Methods A phase I clinical trial was initiated for patients with relapsed myeloma with administration of oral lenalidomide on days 1 to 21 and CCI-779 intravenously once per week during a 28-day cycle. Pharmacokinetic data for both agents were obtained, and in vitro transport and uptake

APA, Harvard, Vancouver, ISO, and other styles

28

Rapp, Robert P. "Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Azithromycin: Enhanced Tissue Activity and Minimal Drug Interactions." Annals of Pharmacotherapy 32, no. 7-8 (1998): 785–93. http://dx.doi.org/10.1345/aph.17299.

Full text

Abstract:

OBJECTIVE: To review the pharmacokinetics and pharmacodynamics of oral and intravenous azithromycin compared with other macrolide antibiotics, and to evaluate these differences and their relation to clinical effectiveness. DATA SOURCE: A MEDLINE search (1966–May 1998) was performed to identify applicable English-language clinical, animal, and microbiologic studies pertaining to pharmacokinetic and pharmacodynamic parameters. STUDY SELECTION: Relevant studies concerning microbiology, pharmacokinetics, tissue concentrations, pharmacodynamics, and the clinical effects of these parameters were sel

APA, Harvard, Vancouver, ISO, and other styles

29

Botts, Sheila R., and Cara Alfaro. "Antidepressant Drug Interactions." Journal of Pharmacy Practice 14, no. 6 (2001): 467–77. http://dx.doi.org/10.1177/089719001129040964.

Full text

Abstract:

Second-generation antidepressants are more selective in their pharmacological mechanisms and offer fewer side effects and a safer toxicological profile than cyclic antidepressants and monoamine oxidase inhibitors. While the risk for pharmacodynamic interactions is more limited than with older agents with broader receptor effects, the risks for pharmacokinetic interactions is greater. The capacity of selective serotonin reuptake inhibitors to inhibit the metabolic activity of cytochrome P450 isozyme system has spurred over a decade of intense psychopharmacological and pharmacogenetics research

APA, Harvard, Vancouver, ISO, and other styles

30

Czyrski, Andrzej, Matylda Resztak, Paweł Świderski, Jan Brylak, and Franciszek K. Główka. "The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles." Pharmaceutics 13, no. 11 (2021): 1961. http://dx.doi.org/10.3390/pharmaceutics13111961.

Full text

Abstract:

Second generation triazoles are widely used as first-line drugs for the treatment of invasive fungal infections, including aspergillosis and candidiasis. This class, along with itraconazole, voriconazole, posaconazole, and isavuconazole, is characterized by a broad range of activity, however, individual drugs vary considerably in safety, tolerability, pharmacokinetics profiles, and interactions with concomitant medications. The interaction may be encountered on the absorption, distribution, metabolism, and elimination (ADME) step. All triazoles as inhibitors or substrates of CYP isoenzymes can

APA, Harvard, Vancouver, ISO, and other styles

31

Crismon, M. Lynn. "Pharmacokinetics and Drug Interactions of Cholinesterase Inhibitors Administered in Alzheimer's Disease." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 18, no. 2P2 (1998): 47–54. http://dx.doi.org/10.1002/j.1875-9114.1998.tb03878.x.

Full text

Abstract:

Cholinesterase inhibitors are the first agents to be successfully developed specifically for the treatment of cognitive decline associated with Alzheimer's disease. Basic knowledge of their pharmacokinetics is important to their appropriate administration. Their pharmacokinetics help determine the magnitude and duration of their pharmacologic effects, and also the manner in which they affect the degree of cholinesterase inhibition and recovery. The clinical utility of measuring these values in daily practice awaits further research. Drug interactions with cholinesterase inhibitors may occur by

APA, Harvard, Vancouver, ISO, and other styles

32

Lesko, L. J. "Pharmacokinetic Drug Interactions with Amiodarone." Clinical Pharmacokinetics 17, no. 2 (1989): 130–40. http://dx.doi.org/10.2165/00003088-198917020-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Venkatesan, K. "Pharmacokinetic Drug Interactions with Rifampicin." Clinical Pharmacokinetics 22, no. 1 (1992): 47–65. http://dx.doi.org/10.2165/00003088-199222010-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Periti, Piero, Teresita Mazzei, Enrico Mini, and Andrea Novelli. "Pharmacokinetic Drug Interactions of Macrolides." Clinical Pharmacokinetics 23, no. 2 (1992): 106–31. http://dx.doi.org/10.2165/00003088-199223020-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Riva, Roberto, Fiorenzo Albani, Manuela Contin, and Agostino Baruzzi. "Pharmacokinetic Interactions Between Antiepileptic Drugs." Clinical Pharmacokinetics 31, no. 6 (1996): 470–93. http://dx.doi.org/10.2165/00003088-199631060-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Giao, Phantrong, and Peter J. de Vries. "Pharmacokinetic Interactions of Antimalarial Agents." Clinical Pharmacokinetics 40, no. 5 (2001): 343–73. http://dx.doi.org/10.2165/00003088-200140050-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Unger, Matthias. "Pharmacokinetic drug interactions involvingGinkgo biloba." Drug Metabolism Reviews 45, no. 3 (2013): 353–85. http://dx.doi.org/10.3109/03602532.2013.815200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Somogyi, Andrew, and Murray Muirhead. "Pharmacokinetic Interactions of Cimetidine 1987." Clinical Pharmacokinetics 12, no. 5 (1987): 321–66. http://dx.doi.org/10.2165/00003088-198712050-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Oesterheld, Jessica R., Scott C. Armstrong, and Kelly L. Cozza. "Ecstasy: Pharmacodynamic and Pharmacokinetic Interactions." Psychosomatics 45, no. 1 (2004): 84–87. http://dx.doi.org/10.1176/appi.psy.45.1.84.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Pleuvry, Barbara J. "Pharmacodynamic and pharmacokinetic drug interactions." Anaesthesia & Intensive Care Medicine 6, no. 4 (2005): 129–33. http://dx.doi.org/10.1383/anes.6.4.129.63634.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Blei, Andres. "Pharmacokinetic-Hemodynamic Interactions in Cirrhosis." Seminars in Liver Disease 6, no. 04 (1986): 299–308. http://dx.doi.org/10.1055/s-2008-1040612.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Back, David, Sara Gibbons, and Saye Khoo. "Pharmacokinetic Drug Interactions with Nevirapine." JAIDS Journal of Acquired Immune Deficiency Syndromes 34 (September 2003): S8—S14. http://dx.doi.org/10.1097/00126334-200309011-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Tarirai, Clemence, Alvaro M. Viljoen, and Josias H. Hamman. "Herb–drug pharmacokinetic interactions reviewed." Expert Opinion on Drug Metabolism & Toxicology 6, no. 12 (2010): 1515–38. http://dx.doi.org/10.1517/17425255.2010.529129.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Brüggemann, Roger J. M., Jan-Willem C. Alffenaar, Nicole M. A. Blijlevens, et al. "Pharmacokinetic drug interactions of azoles." Current Fungal Infection Reports 2, no. 1 (2008): 20–27. http://dx.doi.org/10.1007/s12281-008-0004-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

K, K., K. K, K. K, and K. K. "Oral Pharmacokinetic Drug-drug Interactions between Amifampridine and Acetaminophen in Rats." Yakhak Hoeji 68, no. 2 (2024): 98–104. http://dx.doi.org/10.17480/psk.2024.68.2.98.

Full text

Abstract:

Amifampridine, the first-line medication for Lambert-Eaton myasthenic syndrome (LEMS), is extensively metabolized by N-acetyltransferase 2 (NAT2). Drug-drug interactions (DDIs) can occur when co-administered with a NAT2 inhibitor and amifampridine. Acetaminophen is a widely used analgesic for mild to moderate pain, which is also known as a NAT2 inhibitor. In this work, we studied the effects of acetaminophen on the amifampridine pharmacokinetics in rats. Both acetaminophen (300 mg/kg) and amifampridine (2 mg/kg) were administered orally. In acetaminophen-treated rats, the systemic exposure to

APA, Harvard, Vancouver, ISO, and other styles

46

Knežević, Sandra, Francesca Filippi-Arriaga, Andrej Belančić, Tamara Božina, Jasenka Mršić-Pelčić, and Dinko Vitezić. "Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review." Diabetology 5, no. 4 (2024): 406–29. http://dx.doi.org/10.3390/diabetology5040031.

Full text

Abstract:

Metabolic syndrome (MetS) presents a significant global health challenge, characterized by a cluster of metabolic alterations including obesity, hypertension, insulin resistance/dysglycemia, and atherogenic dyslipidemia. Advances in understanding and pharmacotherapy have added complexity to MetS management, particularly concerning drug interactions and pharmacogenetic variations. Limited literature exists on drug–drug–gene interactions (DDGIs) and drug–drug–transporter gene interactions (DDTGIs), which can significantly impact pharmacokinetics and pharmacodynamics, affecting treatment outcomes

APA, Harvard, Vancouver, ISO, and other styles

47

Choi, Min-Koo, and Im-Sook Song. "Pharmacokinetic Drug–Drug Interactions and Herb–Drug Interactions." Pharmaceutics 13, no. 5 (2021): 610. http://dx.doi.org/10.3390/pharmaceutics13050610.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Albitar, Orwa, Sabariah Noor Harun, Hadzliana Zainal, Baharudin Ibrahim, and Siti Maisharah Sheikh Ghadzi. "Population Pharmacokinetics of Clozapine: A Systematic Review." BioMed Research International 2020 (January 8, 2020): 1–10. http://dx.doi.org/10.1155/2020/9872936.

Full text

Abstract:

Background and Objective. Clozapine is a second-generation antipsychotic drug that is considered the most effective treatment for refractory schizophrenia. Several clozapine population pharmacokinetic models have been introduced in the last decades. Thus, a systematic review was performed (i) to compare published pharmacokinetics models and (ii) to summarize and explore identified covariates influencing the clozapine pharmacokinetics models. Methods. A search of publications for population pharmacokinetic analyses of clozapine either in healthy volunteers or patients from inception to April 20

APA, Harvard, Vancouver, ISO, and other styles

49

Rodriguez-Vera, Leyanis, Xuefen Yin, Mohammed Almoslem, et al. "Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin." Pharmaceutics 15, no. 10 (2023): 2486. http://dx.doi.org/10.3390/pharmaceutics15102486.

Full text

Abstract:

Regulatory agencies worldwide expect that clinical pharmacokinetic drug–drug interactions (DDIs) between an investigational new drug and other drugs should be conducted during drug development as part of an adequate assessment of the drug’s safety and efficacy. However, it is neither time nor cost efficient to test all possible DDI scenarios clinically. Phenytoin is classified by the Food and Drug Administration as a strong clinical index inducer of CYP3A4, and a moderate sensitive substrate of CYP2C9. A physiologically based pharmacokinetic (PBPK) platform model was developed using GastroPlus

APA, Harvard, Vancouver, ISO, and other styles

50

Li, Ying, Yin Wu, Ya-Jing Li, Lu Meng, Cong-Yang Ding, and Zhan-Jun Dong. "Effects of Silymarin on the In Vivo Pharmacokinetics of Simvastatin and Its Active Metabolite in Rats." Molecules 24, no. 9 (2019): 1666. http://dx.doi.org/10.3390/molecules24091666.

Full text

Abstract:

Herein, the effect of silymarin pretreatment on the pharmacokinetics of simvastatin in rats was evaluated. To ensure the accuracy of the results, a rapid and sensitive UPLC–MS/MS method was established for simultaneous quantification of simvastatin (SV) and its active metabolite simvastatin acid (SVA). This method was applied for studying the pharmacokinetic interactions in rats after oral co-administration of silymarin (45 mg/kg) and different concentrations of SV. The major pharmacokinetic parameters, including Cmax, tmax, t1/2, mean residence time (MRT), elimination rate constant (λz) and a

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!